{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:30:31Z","timestamp":1790497831932,"version":"4.1.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T00:00:00Z","timestamp":1393891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089527","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T22:46:36Z","timestamp":1393973196000},"page":"e89527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma"],"prefix":"10.1371","volume":"9","author":[{"given":"\u00d8ystein","family":"Helland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Popa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav K.","family":"Vintermyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Molven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"A Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.31589","article-title":"Surgical management of ovarian cancer","volume":"29","author":"DG Mutch","year":"2002","journal-title":"Semin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ygyno.2008.11.033","article-title":"Advanced cytoreductive surgery: American perspective","volume":"114","author":"O Zivanovic","year":"2009","journal-title":"Gynecol Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"RF Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1008355317514","article-title":"First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer\u2013a new standard of care","volume":"10","author":"A du Bois","year":"1999","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"R Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.4161\/cbt.213","article-title":"Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved","volume":"2","author":"RS Kerbel","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-0-387-98094-2_17","article-title":"Animal models of ovarian cancer","volume":"149","author":"DC Connolly","year":"2009","journal-title":"Cancer Treat Res"},{"key":"ref9","first-page":"4227","article-title":"Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models","volume":"9","author":"T Voskoglou-Nomikos","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ctrv.2013.01.005","article-title":"Revisiting ovarian cancer preclinical models: Implications for a better management of the disease","volume":"39","author":"F Ricci","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ymthe.2005.03.026","article-title":"HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer","volume":"12","author":"F Benencia","year":"2005","journal-title":"Mol Ther"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/JCO.2011.36.9678","article-title":"Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft","volume":"30","author":"MP Morelli","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","article-title":"Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages","volume":"40","author":"MC Bibby","year":"2004","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1535-7163.MCT-06-0391","article-title":"Tumor models for efficacy determination","volume":"5","author":"BA Teicher","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref15","article-title":"In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer","author":"AB Cordero","year":"2010","journal-title":"J Vis Exp"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1593\/neo.111076","article-title":"Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4","volume":"13","author":"P Ray","year":"2011","journal-title":"Neoplasia"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1158\/1078-0432.CCR-11-1388","article-title":"Preclinical testing of PI3K\/AKT\/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma","volume":"17","author":"R Wu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e24420","DOI":"10.1371\/journal.pone.0024420","article-title":"Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis","volume":"6","author":"RB Bankert","year":"2011","journal-title":"PLoS One"},{"key":"ref19","first-page":"111","article-title":"Surgical debulking of ovarian cancer: what difference does it make?","volume":"3","author":"JO Schorge","year":"2010","journal-title":"Rev Obstet Gynecol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/bjc.2012.261","article-title":"Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models","volume":"107","author":"P Oliva","year":"2012","journal-title":"Br J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bjc.6602334","article-title":"Ascitic complement system in ovarian cancer","volume":"92","author":"L Bjorge","year":"2005","journal-title":"Br J Cancer"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/viro.2000.0353","article-title":"Optimization of regulated LTR-mediated expression","volume":"272","author":"JB Lorens","year":"2000","journal-title":"Virology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.yexcr.2010.10.009","article-title":"Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model","volume":"317","author":"XS Ke","year":"2011","journal-title":"Exp Cell Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"ref25","first-page":"553","article-title":"A mouse surgical model for metastatic ovarian granulosa cell tumor","volume":"59","author":"ME Nadeau","year":"2009","journal-title":"Comp Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"501.e501","DOI":"10.1016\/j.ajog.2013.03.012","article-title":"Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers","volume":"208","author":"P Teefey","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"E McCormack","year":"2012","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1073\/pnas.1005529108","article-title":"Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells","volume":"108","author":"JM Stewart","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"CT Griffiths","year":"1975","journal-title":"Natl Cancer Inst Monogr"},{"key":"ref30","first-page":"413","article-title":"Primary cytoreductive surgery for epithelial ovarian cancer","volume":"61","author":"NF Hacker","year":"1983","journal-title":"Obstet Gynecol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2007.02.026","article-title":"Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)","volume":"106","author":"P Wimberger","year":"2007","journal-title":"Gynecol Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"TJ Shaw","year":"2004","journal-title":"Mol Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1023\/A:1006537013317","article-title":"A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer","volume":"16","author":"K Kiguchi","year":"1998","journal-title":"Clin Exp Metastasis"},{"key":"ref34","first-page":"283","article-title":"Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens","volume":"13","author":"X Fu","year":"1993","journal-title":"Anticancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation","volume":"29","author":"G Singer","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"ref36","first-page":"175","article-title":"Co-expression of cytokeratin and vimentin filaments in mesothelial, granulosa and rete ovarii cells of the human ovary","volume":"37","author":"B Czernobilsky","year":"1985","journal-title":"Eur J Cell Biol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"YS DeRose","year":"2011","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"S Domcke","year":"2013","journal-title":"Nat Commun"},{"key":"ref39","article-title":"Sonoporation-Enhanced Chemotherapy Significantly Reduces Primary Tumour Burden in an Orthotopic Pancreatic Cancer Xenograft","author":"S Kotopoulis","year":"2013","journal-title":"Mol Imaging Biol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2310\/7290.2012.00029","article-title":"In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme","volume":"12","author":"MA Jarzabek","year":"2013","journal-title":"Mol Imaging"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2990.2010.01119.x","article-title":"A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients","volume":"37","author":"J Wang","year":"2011","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cncr.2820710205","article-title":"Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality","volume":"71","author":"R Yancik","year":"1993","journal-title":"Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"RE Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"MJ Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results","volume":"17","author":"GM van Dam","year":"2011","journal-title":"Nat Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ygyno.2012.12.011","article-title":"Real-time near infrared fluorescence (NIRF) intra-operative imaging in ovarian cancer using an alpha(v)beta(3-)integrin targeted agent","volume":"128","author":"NJ Harlaar","year":"2013","journal-title":"Gynecol Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.2967\/jnumed.111.092833","article-title":"Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies","volume":"52","author":"AG Terwisscha van Scheltinga","year":"2011","journal-title":"J Nucl Med"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","article-title":"Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer","volume":"18","author":"A Vidal","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T04:43:33Z","timestamp":1565239413000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089527"}},"subtitle":[],"editor":[{"given":"Viji","family":"Shridhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089527","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]}}}